Craft

Agios Pharmaceuticals

Stock Price

$42

2024-07-02

Market Capitalization

$2.4 B

2024-07-02

Revenue

$26.8 M

FY, 2023

Agios Pharmaceuticals Summary

Company Summary

Overview
Agios Pharmaceuticals is a biopharmaceutical company passionately committed to applying its scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism, which are a subset of orphan genetic metabolic diseases.Agios is a first mover in using cellular metabolism, an unexploited area of biological research with disruptive potential, as a platform for developing potentially transformative medicines. The Company intends to apply its deep understanding of metabolism, coupled with its ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and rare genetic disorders of metabolism are treated.Agios also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The Company's therapeutics are used in the areas of autoimmune, inflammatory, and neurological diseases.
Type
Public
Status
Active
Founded
2008
HQ
Cambridge, MA, US | view all locations
Website
http://www.agios.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Brian Goff

    Brian Goff, Chief Executive Officer

    • Scott Biller

      Scott Biller, Scientific Advisory Board member

    • Jim Burns
    • Sarah Gheuens

      Sarah Gheuens, Chief Medical Officer, Head of R&D

    LocationsView all

    1 location detected

    • Cambridge, MA HQ

      United States

      88 Sidney St

    Agios Pharmaceuticals Financials

    Summary Financials

    Revenue (Q1, 2024)
    $8.2M
    Gross profit (Q1, 2024)
    $7.6M
    Net income (Q1, 2024)
    ($81.5M)
    Cash (Q1, 2024)
    $118.8M
    EBIT (Q1, 2024)
    ($92.1M)
    Enterprise value
    $2.3B

    Footer menu